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Abstract
Here we report the systematic study of the anti-trypanocidal activity of some new products derived from S. diastatus on 14
different T. cruzi strains spanning the six genetic lineages of T. cruzi. As the traditional growth inhibition curves giving similar
IC50 showed great differences on antibiotic and lineage tested, we decided to preserve the wealth of information derived
from each inhibition curve and used an algorithm related to potency of the drugs, combined in a matrix data set used to
generate a cluster tree. The cluster thus generated based just on drug susceptibility data closely resembles the phylogenies
of the lineages derived from genetic data and provides a novel approach to correlate genetic data with phenotypes related
to pathogenesis of Chagas disease. Furthermore we provide clues on the drugs mechanism of action.
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Introduction
Chagas disease or American Trypanosomiasis is a chronic
illness caused by the Kinetoplastid protozoan Trypanosoma cruzi. At
present it represents the third largest parasitic disease burden in
the world and the largest in the western hemisphere. It is endemic
in Central and South America with over 10 million people
currently affected, with 40–100 million (15–20%of the whole Latin
American population) at risk of acquiring the disease, killing
around 15000 people annually [1,2].
In the past decades, mainly because of increased population
movements, the number of diagnosed cases has increased also in
non-endemic countries in the Region of the Americas (Canada
and United States of America), and in Europe (principally in
Spain, Belgium, France, Italy, Switzerland and United Kingdom
of Great Britain and Northern Ireland) [3–5] and the Western
Pacific regions (Australia and Japan). This increase presents
additional risks of transmission of the parasite through blood
transfusion, congenital infection and organ transplantation [6].
The complex pathogenesis of the disease starts with a low
mortality initial acute phase with generally mild and unspecific
symptoms in which Th1 lymphocytes, IFN-gamma and macro-
phages are in charge of controlling parasite replication [7–9].This
leads to a long lasting chronic condition in which the cellular
immune responses fight to unsuccessfully limit parasite prolifera-
tion and elimination, resulting in a sustained inflammatory
response that triggers the development of one or more of the
diverse and geographically divergent symptomatic clinic forms of
the disease that emerges in 20–40% of patients such as chronic
chagasic cardiomyophaty (CCC), digestive problems like mega-
esophagous and megacolon and neuropathies [7,10–14], which
may appear decades after the initial infection.
It remains unexplained why different patients develop the
cardiac, digestive, cardio-digestive or indeterminate clinical forms.
One possible clue is a significant geographical variation in the
prevalence and severity of the different forms of the disease. It is
believed that this geographical heterogeneity is caused primarily
by genetic variation of T. cruzi, since it does not present a clear
correlation with any pattern of ethnic or human genetic or
environmental variables [15].
The parasite role on the acute phase pathology is unquestion-
able; however there have been controversy over the years on its
influence on its participation in the chronic phase pathogenesis
[16–19], but the consensus growing over the least years is that the
persistence of parasites (clonal or mixed population), coupled with
an unbalanced immune response leads in susceptible individuals
combined to infecting strain(s) virulence, to a sustained inflam-
matory responses that underlies the lesions of chronic Chagas
disease. This implies that eradication of T. cruzi parasites in the
host tissue is an ineludible condition to arrest the evolution of the
disease.
Efficacy of current chemotherapy of Chagas disease is
controversial as the two drugs in use, Nifurtimox (NFX; LampitH)
and Benznidazol (BZN, RochaganH, RadanilH) have severe side
effects [20–23], and are at the best moderately effective in the
chronic stages of infection, besides requiring long courses of
PLOS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40901
treatment without specific pediatric formulations [24,25] and there
is a great deal of different activity towards the different strains
belonging to the six genetic lineages of T. cruzi [26], without any
attempts to establish correlations [27–30].
Over the last three decades, a great effort has been made to
reduce the vectorial and transfusional transmission of Chagas
disease in some endemic areas through the interruption of
reservoir to human and human to human propagation [31,32]
however, there is consensus that this neglected illness cannot be
totally eradicated with the current measure and intervention tools.
Thus, it is urgent to continue the development of new therapeutic
tools and to carry out surveys of new anti-trypanocidal drugs on a
wide array of strains as a complementary way to evaluate
biochemical distinctive traits that can be correlated to the clinical
forms of the disease.
Our group reported recently the antifungal activity of a new
macrolide antibiotic [33] CE-108 from Streptomyces diastaticus 108
with some activity against T. cruzi [34]. Here we report the
systematic study of the anti-trypanocidal activity of some new
products derived from S. diastatus on 14 different T. cruzi strains
representing the six genetic lineages of T. cruzi [26] and provide
clues on the action mechanism. Furthermore, preserving the
wealth of information derived from each inhibition curve, we used
an algorithm related to potency of the drugs on epimastigotes,
combined in a matrix data set used to generate a cluster tree that
closely resembles the phylogenies of the lineages derived from
genetic data.
Materials and Methods
Cells and Parasites
Vero (green monkey kidney cells, ATCC CCL-81) and LLC-
MK2 (Rhesus kidney cells, ATCC CCL-7) cell lines were both
obtained from ATCC and grown in 24 wells plates in RPMI
medium supplemented with 7.5% FCS, humidified 5% CO2.
The different strains of Trypanosoma cruzi used are indicated in
Table 1, and were obtained through ChagasEPInet Consortia
(http://www.ki.se/chagasepinet/), and grown as epimastigotes in
RPMI +10% FCS at 28uC, by passages every five days. Metacyclic
trypomastigotes forms of selected strains were obtained from the
supernatant of infected Vero cells and isolated by differential
centrifugation.
Infection Assays
Vero or LLC-MK2 cells growing on glass coverslips at 25%
confluency in 24 well plates were infected with tripomastigotes at
an infection index of 10 during for 4 hours. The cells were washed
three times to remove unattached parasites and kept at 37uC with
or without drugs for the indicated times and concentrations.
At indicated times; cells were washed twice with PBS, fixed with
Bouins fixative solution and stained in Giemsa solution. The
intracellular amastigotes were quantified counting randomly at
least 300 cells.
Drugs
The drugs used (AB-400 (AB), Pimaricin (PIM), CE-108B, CE-
108D, CE-108E) were obtained and purified as described before
[33–36]. Briefly, when needed, the polyenes were weighted,
dissolved in dimethyl sulphoxide (DMSO) and diluted with
medium up to the required concentration immediately prior to
each experiment. The final DMSO concentration in the culture
never exceeded 0.2%.
Benznidazole (Rochagan) was provided by M. Miles at the
London School of Hygiene and Tropical Medicine, London, UK.
Toxicity and Viability Assays
For anti-trypanocidal assays on epimastigotes, the parasites
(50000 cells, mid-log) were grown in 96 wells plates in a volume of
200 microliters to which the drugs were added at the indicated
final concentrations and the growth followed during seven days by
measuring Optical Density at 600 nm. Control wells containing
media and vehicle of the drugs (DMSO) were included. Three
replicate plates were used for each drug. The drug concentration
that inhibits 50% growth was estimated by plotting the parasite
numbers at different days as a percentage over dug concentration.
Metacyclic trypomastigote forms (16106 cells/ml) were main-
tained at 37uC in RPMI medium supplemented with 10% FBS
and then incubated for 24 h with different concentrations (1–
100 mM) of the drugs, final volume 100 ml in microtiter plates. The
IC50 (concentration that lyses 50% of the parasites) was then
evaluated by counting the cells in a Neubauer chamber. Each test
was made in two experiments conducted in duplicate.
To evaluate the toxicity and viability effects of the drugs on
mammalian cells the MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide) was used as reported [37] on cells
growing in 96 wells plates.
Once toxicity on cells was determined, treatment with the drugs
was performed by two protocols: (1) pretreatment: incubate cells
with drugs during the four hour infection period and keep the
drugs in media after washing the unattached parasites, and (2) add
the drugs 24 hours post infection and keep them for the duration
of the experiment.
Electron Microscopy
For scanning electron microscopy, the parasites drug treated
and control, were adhered to poly-L-lysine-coated coverslips, fixed
with 2.5% glutaraldehyde in 0.1 M Na-cacodylate buffer (pH 7.2)
at room temperature for 40 minutes and post-fixed with a solution
of 1% OsO4, 0.8% potassium ferricyanide and 2.5 mM CaCl2 in
the same buffer for 20 min. The cells were dehydrated in an
ascending acetone series and dried by the critical point method
Table 1. Relation of strains used on this study, with
adscription to genetic lineage, geographical origin and host
from which was isolated.
Strain Lineage Origin Host/Vector
Silvio/X10 c1 TcI Belem, Brazil Homo sapiens
C8 c1 TcI La Paz, Bolivia Triatoma infestans
Dm28c TcI Carabobo, Venezuela Didelphis marsupialis
Esmeraldo c3 TcII Bahia, Brazil Homo sapiens
Y TcII Sao Paulo, Brazil Homo sapiens
Tu18 c2 TcII Tupiza, Bolivia Triatoma infestans
Cm17 TcIII Carimaga, Colombia Dasyprocta fugilinosa
M6241 c6 TcIII Para, Brazil Homo sapiens
10R26 TcIV Santa Cruz, Bolivia Aotus sp.
Bug2148 c11 TcV Rio Grande do Sul, Brazil Triatoma infestans
Sc43 c1 TcV Santa Cruz, Bolivia Triatoma infestans
Tula c2 TcVI Tulahuen, Chile Homo sapiens
VFRA c1 TcVI Francia, Chile Triatoma infestans
CL-Brener TcVI Rio Grande do Sul, Brazil Triatoma infestans
All indicated strains were obtained through the ChagasEPINet Consortia (http://
www.ki.se/chagasepinet/).
doi:10.1371/journal.pone.0040901.t001
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with CO2. The samples were mounted in aluminium stubs, coated
with a 20 nm thick gold layer and examined in a Hitachi S-3000N
scanning electron microscope (SEM).
Flow Cytometry
Epimastigotes (56106 cells/ml) were treated at the times and
doses indicated at 28uC. Thereafter the cells were incubated for
15 min with 10 mg/ml tetramethyrhodamine methylesther
(TMRM, Invitrogen) and kept on ice until analysis. Data
acquisition and analysis were done on a FACSCalibur flow
cytometer (Becton-Dickinson, CA, USA) and Cell Quest software.
Ten thousand events were acquired. Alterations in the fluores-
cence for TMRM were quantified using an index of variation (IV)
obtained by the equation (MT-MC)/MC were MT is the median of
fluorescence for treated parasites and MC that of control cells
(Menna-Barreto, 2005). A negative value for IV corresponds to
depolarization of the mitochondrial membrane. In some experi-
ments we used rhodamine 123 (Rh123) as fluorescent probe
obtaining the same results as with Rh123.
For analysis of viability and exposure of PS, the epimastigotes,
after treatment with the drugs were stained with 10 mg/ml of
propidium iodide (PI) and with 1 mg/ml annexin V-FITC,
respectively, for 30 minutes. Data acquisition was done as
described before.
Clustering
The inhibition produced by each antibiotic on a given strain
was measured by using an algorithm which is described [38] as:
Figure 1. Representative dose-viability curves of PIM and CE108B on different DTUs after 72 hours incubation. Epimastigotes of
indicated DTUs were incubated with the drug for 72 hours in the microtiter plate assay as described in Materials and Methods. It shows the growth
inhibition compared to control cultures without any drug (shown media of three experiments in triplicate).
doi:10.1371/journal.pone.0040901.g001
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Inhibition value(Iv)~
X10{4
10{7
Ici({ log ci)
Where Ci represents each one of the micromolar antibiotic
concentrations tested (0.1, 0.3, 1, 3, 10, 30, and 100) and Ici the
percentage of growth inhibition at the Ci concentration when
compared with untreated control. The application of this
algorithm yields dimensionless values for each pairwise strain-
antibiotic. The pairwise values obtained were used to generate a
cluster tree to show relationships between strains, Wards method,
single linkage and complete linkage hierarchical cluster analysis
methods were used to group strains, and a French PCA was run in
Statistica version 8 (www.statsoft.com) to determine the similarities
between the strains. To establish if a correlation exists between
genetic distances (obtained from the literature [39,40] and the
Euclidean distances obtained in this report, a Mantel test [41] was
used.
Results
Effect on Epimastigotes
On Fig. 1 are shown representative dose dependent growth
inhibition curves for some DTUs at 48 hours. All the strains
indicated on Table 1 were susceptible to the antibiotics tested
but differed remarkably on the shape of the dose dependence,
indicating different susceptibilities thresholds or differential
accumulative effects. Routinely, one out of two measures was
done by counting cells also to corroborate correlation between
OD and cell number. The Table 2 reports the IC50 for all
strains against all antibiotics (and benznidazol as a control drug)
tested at 48 hours.
Effect on Metacyclic Trypomastigotes
We decided to test the activity of some selected antibiotics (PIM,
CE108B, CE108E) on metacyclic trypomastigotes viability to
validate any antitrypanocidal effect and to verify that any
correlation data obtained from epimastigotes would remain valid
to trypomastigotes. The data are summarized in Table 3 indicate
that the antibiotics tested exhibit antitrypanocidal effects on that
life form of the parasite. It is possible to establish a correlation
between the effects seen against non-infective epimastigotes and
those seen on metacyclic tripomastigotes, thus strains from DTUs
IV and V (Sc43 and 10R26) were the less susceptible to the tested
antibiotics, in contrast to DTUs I, II and VI that exhibit a greater
susceptibility to the drugs. In any case, it is significative that
trypomastigotes in all cases exhibited a higher susceptibility than
the epimastigotes counterpart.
Cytotoxic Activity
Before analyzing the effect of the drugs on intracellular
amastigotes we evaluated the toxicity on cultured mammalian
host cell lines Vero and LLC-MK2. On both cell lines, the viability
starts being compromised at concentrations above 100 mM with all
the antibiotics tested at times above 48 hours of incubation. We
observed that antibiotics CE108, CE108B and CE108D, always
result less toxic to the cells when compared with AB and PIM. Due
to sample limitations the toxic effect of CE108E was only tested at
10 mM, concentration at which exhibited a behavior similar to
CE108B. At the concentrations effective on the epimastigotes
growth and trypomastigotes viability (1–10 mM), the viability was
never below 90% after 96 hours incubation, with the only
exception of Vero cells treated with 10 mM PIM, that showed a
viability of 80% after 96 h treatment.
Effect on Amastigotes
Once confirmed the low toxicity on host cells, the effect of
CE108B, CE108E and Pim (the drugs with overall lower IC50)
on metacyclic trypomastigotes and proliferating epimastigotes
was evaluated on six strains of T. cruzi, Silvio/X10 (TcI), Y
(TcII), CM17 (TcIII), 10R26 (TcIV), Sc43 (Tc V) and Cl-
Brener (TcVI) infecting LLc-MK2 or Vero cells. It was
evaluated following two protocols as indicated in Material and
Methods. In one protocol, the drugs were added during the four
hours infection period and kept during the proliferation of
amastigotes intracellularly. In the second protocol, the drugs
were added to the culture medium 24 h after the infection. The
concentration used for testing efficacy was 5 mM in all cases.
The cultures were evaluated 3 days after infection and the
percentage of infected cells as well as the number of amastigotes
per cell was quantified by counting not less than 300 cells. The
results shown in Fig. 2 indicate that all three antibiotics tested
are effective against the six strains evaluated. In all cases the
pre-treatment, even for a short 4 hour period, resulted in a
higher infection blocking efficacy, probably due to higher
effective concentration affecting the ability of parasite to
Table 2. Trypanocidal activity of antibiotics and Benznidazol
(BZN) on epimastigote form.
Strain PIM CE108 CE108B CE108D CE108E AB400 BZN
Silvio/X10 c11 0.8 3.5 2.1 4.2 3.9 3.2 31.8
C8 1.8 3.8 3.8 6.3 3.7 2.5 25.7
Dm28c 1.1 2.9 4 5.9 4.1 3.7 22.2
Esmeraldo c13 0.9 3.9 2.9 5.1 5.2 nd 30.5
Y 0.8 3.7 3.1 4.9 5.5 2.5 12.4
Tu18 1.2 4.1 3.2 5.4 4.8 2.7 15.1
Cm17 0.8 2.1 0.9 1.5 1.8 1.2 10.4
M6241 cl6 1.1 2.4 0.8 1.8 2 nd 12.1
10R26 10.5 8.1 12 7.8 9 10.2 22.4
Bug2148 c11 21 18 25 31 27 17 28.1
Sc43 c11 40 22 30 45 38 21 21.4
Tula 1.5 3.5 2.9 2.5 3.8 2.8 16.2
VFRA 0.9 2.8 3.5 5.2 6.1 4.3 11.2
CL-Brener 0.9 3.2 4.1 4.2 5.9 2.4 15.8
doi:10.1371/journal.pone.0040901.t002
Table 3. Activity on metacyclic tripomastigotes.
Strain PIM CE108 CE108B CE108D CE108E AB400 BZN
Silvio/X10 0.5 nd 0.8 nd 0.4 nd 12.4
Y 0.5 nd 1.8 nd 2.1 nd 8.1
CM17 0.8 nd 2.2 nd 0.5 nd 11.4
10R26 4 nd 3.5 nd 3.1 nd 16.2
Sc43 c11 14 nd 2.8 nd 7.2 nd 13.2
CL-Brener 0.5 nd 0.9 nd 0.3 nd 7.8
The table shows the effective concentration causing 50% growth inhibition at
72 hours compared to untreated control culture (IC50) in micromolar.
doi:10.1371/journal.pone.0040901.t003
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Figure 2. Effect of antibiotics on in vitro infection and intracellular amastigotes. LLC-MK2 cells were infected with bloodstream
trypomastigotes of the indicated DTUs as detailed in Materials and Methods. Two different protocols were used, PRE: the drugs were added during
Susceptibility to Drugs Related to Genetic Lineage
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penetrate the cells and establish a productive infection. The
efficacy ranking of the antibiotics on amastigotes development
(measured as the difference in % of infected cells in treated vs.
control cultures) could be correlated to the IC50 on prolifer-
ating epimastigotes, thus the DTUs IV and V showed to be less
susceptible to the drugs. We were not able to find a significant
difference on the number of amastigotes per cells between the
two different protocols; however this was the case when the
number of infected cells was considered, where the pretreatment
resulted in a statistically significant lower number of infected
cells.
Flow Cytometry
PS exposure in the outer leaflet of the plasma membrane is a
common feature of eukaryotic cells undergoing death by apoptosis.
By using annexin V-FITC and PI, PS exposure and membrane
permeability of parasites exposed to the antibiotics were simulta-
neously accessed. Untreated parasites were annexin V and PI
negative (not shown). The Fig. 3 shows a cytometry dose
dependence profile of annexin-V and PI staining for Silvio/X10
strain at 4 h incubation with PIM (A) and CE108B (B). This is a
representative profile common to all the strains and antibiotics
tested, in which PIM is showing effect at lower concentrations, at
least to what concerns to increase in permeability, and continue
with exposure of PS.
In addition, alterations on the mitochondrial membrane
potential of epimastigotes treated with different antibiotic concen-
trations for 4 hours were studied. Fig. 4 shows a representative
experiment showing a drastic reduction of the median value of
fluorescence of TMRM upon increasing antibiotic concentration
indicating loss of mitochondrial potential of the epimastigotes.
Table 4 presents a summary of IV values for the strains used for
the two antibiotics tested in this analysis. It is possible to
discriminate two behaviors regarding the threshold of effect, in
some strains there is a gradual dose dependent effect on the
membrane potential and on others there is sudden change from
the four hours infection period and kept during the proliferation of amastigotes intracellularly. In the second protocol (POST), the drugs were added
to the culture medium 24 h after the infection. After four days, the cultures were processed as described and not less than 300 cells were counted
by two independent observers. A.- Shows the percentage of infected cells. B.- Shows the number of amastigotes per infected cell.
doi:10.1371/journal.pone.0040901.g002
Figure 3. PS exposure and membrane permeability changes induced by the antibiotics. Epimastigotes of Silvio/X10 strain were treated
with PIM (A) or CE108B (B) during 4 hours with the indicated drug concentrations. Representative dot-plots of parasites stained for PS exposure
(Annexin V, X-axis) and membrane permeability (PI staining, Y-axis).
doi:10.1371/journal.pone.0040901.g003
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almost no effect to total dissipation of membrane potential when
moving from 0.4 to 4 mM of antibiotic. The same behavior was
noticed when the incubation time was increased to 24 hours (not
shown).
Ultrastructural Analysis
The parasites from strain CM17 and Silvio/X10 were treated
with different dose for different times with Silvio/X10 and
CE108B and analyzed by SEM. The Fig. 5a and b, presents the
control parasites showing the typical elongated body, smooth
surface with terminal flagellum. Treatment with PIM for 4
hours at 0.4 mM induce some ruffling and blebbing of the
membrane as seen in Fig. 5c, d and e. Increasing the
concentration at 4 mM, or the time at 0.4 mM to 24 h results
in dramatic structural alterations as shown in Fig. 5f, h and i, in
which it can be seen the parasite with large holes on the
membrane from which loss of internal content is evident (arrow
in panel i), body retraction and detachment of flagella. We did
not identify differences in the kinetics of appearance of
ultrastructural alterations among the strains examined. There
are no significant differences in the morphological alterations
upon CE108B (Fig. 5g).
Functional Correlation
In order to gain some insight on a comparative functional
analysis of the different lineages and take profit of the great deal of
information stored on the growth inhibitory data (shape of curve,
range of inhibition) we used the algorithm (see Material and
Methods) that transforms each inhibition curve into a dimension-
less value that represents T. cruzi strain sensitivity. The figure 6
shows the cluster obtained by using the Wards method analysis,
comparing the sensitivity to different antibiotics (PIM, CE108,
CE108B, CE108D and CE108E). The antibiotic AB400 was not
included in the analysis as we do not have the full dose-response
curves for all strains (for some strains we have just 4 concentrations
instead of the seven-eight with the rest). BZN was excluded as the
presumed action mechanism is different to the antibiotics
described here, and no cross-resistance has been found in the
literature (65). The results of such analysis reveal a correlation
between the phylogenetic data based on sequences derived from
miniexon, 16 S rRNA and population genetics, and the functional
data reported here on antibiotic sensitivity. The figure shows that
the strains pertaining to DTU V and IV (only strain 10R26) are
clearly separated and distinct from the DTU I-III and VI. At the
same time, DTU I and II are relatively well defined from each
other as independent groups. The relationship between DTUs VI
Figure 4. Antibiotic treatment caused loss of DYm in epimastigotes. Representative histograms plots showing TMRM staining of Silvio/X10
and CM17 epimastigotes treated or not with PIM and CE108B during 4 hours at indicated concentrations in micromolar. NS: Not stained; NT: Not
treated.
doi:10.1371/journal.pone.0040901.g004
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and III remains less clear, however the correlation between other
genetic markers [39,42–45] and the Euclidean distances is still
significant (data not shown). Similar clusters were obtained by
single or complete linkage analysis. However, the cluster obtained
in this report does not reveal the same topology as the ones
obtained by analysis of genetic markers [39,40,42,44,45].
Discussion
The limitations and drawbacks of the current chemotherapy for
Chagas’ disease highlight the determination for the identification
and evaluation of novel trypanocidal compounds [23,46]. Here we
present data on novel macrolide antibiotics derived from
Streptomyces diastaticus that show higher anti-trypanosomal activity
in vitro than the standard used drug Benznidazol, with significant
lower IC50. These antibiotics exhibit activity against all stages of
development with low toxicity on host cells. The effect on
amastigotes was evaluated under two protocols, pretreatment with
the antibiotics during the binding/attachment/infection period
(pre), and treatment 24 h after initial infection (post). In both cases
we observed a decrease of the percent of infection and of the
number of intracellular amastigotes, but did not observe an
alteration on the differentiation to trypomastigotes in treated
cultures. The difference between pre and post-treatment may be
attributed to higher active concentration of active compound and
its effects on viability of parasite before or during the infection
event. It is important to note that treatment within the time span
of those experiments caused no damage to the cell lines studied as
judged by microscopy and later confirmed by the toxicity assays.
The limited available data on the susceptibility on the
amastigotes (only studied six and not the whole set of 14 strains),
and the fact that we have just studied one concentration instead of
the full inhibition curve, imposes some limitations on the final
analysis and make comparisons difficult, however we can establish
some correlation with the epimastigotes susceptibility. The same
occurs with the metacyclic tripomastigotes, thus strains from
DTUs IV and V are the ones that showed lower susceptibility to
the drugs no matter the developmental stage studied. It is clear
that a systematic and more detailed study on clinically relevant
forms has to be made before any extrapolation of medical
significance.
Considering the ultrastructural alterations, membrane blebbing
is indicative of apoptosis-like; and plasma membrane rupture is
indicative of necrosis [47]. The characterization of programmed
cell death or apoptosis-like pathways in protozoa is under
discussion [48–50], even when some key components directly
involved in the proteolytic machinery that mediates apoptotic cell
death have been identified in such organisms [51–55] with not yet
defined functional involvement [56]. We have observed both
alterations suggesting interplay of different cell death pathways in
the antibiotics effect on epimastigotes; however a more detailed
study by transmission electron microscopy would need to be
performed before assuming a conclusion. Mitochondria play
important roles in both the life and death of cells, as not only
involves respiration, but also in the death signaling pathways,
induced by several stimuli [57]. The treatment with the antibiotics
reported here provokes a drastic drop in fluorescence of both
TMRM and Rh123 (not shown) suggesting interference with
proton electrochemical potential gradient of the mitochondrial
membrane at short times incubation leading most probably to
organelle damage. The reduced retention of the fluorescent probes
was not entirely due to plasma membrane permeabilization as the
percentage of PI positive cells at some treatment conditions was
not higher than 5% in cases in which there was a reduction on the
IV value from control to 20.56, but cannot totally ruled out.
However, in some of the images of SEM, it can be seen abnormal
internal structures protruding; the largest subcellular structure in
T. cruzi is the mitochondria. As we stated before, transmission
electron microscopy analysis have to be performed in order to
confirm damage to this organelle and others like Golgi apparatus
or Endoplasmic Reticulum and disclose the trypanocidal action of
those compounds.
The shape of the dose-effect curves were different fort each
antibiotic and cell strain, so we wanted to take profit of that stored
information. With that objective we implemented the algorithm
already described [38] to cluster all the strains analyzed here based
on the novel macrolide antibiotic susceptibility.
The results, showed an organization of the tested strains in
groups that closely resembles the up to now six groups [26]
obtained by genetic methods derived from sequences of diverse
markers and named genetic lineages or more appropriately
Discrete Typing Units (DTUs) [15,58,59].
The clonal nature of Trypanosoma cruzi postulated some years ago
[60,61] put forward that a correlation between the phylogenetic
divergence of the clones and their biological properties may exist.
Under this premise several reports have appeared exploring
possible links between the biological diversity of T. cruzi and some
biological properties like tissue tropism, virulence, infectivity, drug
(benznidazol or nifurtimox) susceptibility or resistance, replication
rates, metacyclogenesis rate [62], vector and geographical
distribution and even membrane markers, like the trans-sialidase
[63], gp90 [64] or Peanut agglutinin ligands [65]. Regarding drug
susceptibility/resistance, is the biological property that most
attention has received due to the therapeutic/clinical relevance.
Several reports [66–68], sometimes conflicting [28,66–68], using
variable but normally non-reference or low number of strains, and
Table 4. Summary of antibiotic treatment effect on the
mitochondrial membrane potential.
Strain Conc (mM) IV
PIM CE108B
Silvio/X10 c11 0.04 20.28 20.56
0.4 20.73 20.82
4 20.99 20.99
Y 0.04 20.04 20.06
0.4 20.09 20.15
4 20.95 20.98
Cm17 0.04 20.02 20.05
0.4 20.06 20.45
4 20.88 20.91
10R26 0.04 20.04 20.10
0.4 20.18 20.21
4 20.35 20.38
Sc43 c11 0.04 20.02 20.08
0.4 20.08 20.12
4 20.19 20.23
CL-Brener 0.04 20.09 20.1
0.4 20.32 20.41
4 20.87 20.91
IV: Index of variation as defined in Materials and Methods.
doi:10.1371/journal.pone.0040901.t004
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more important, most of the work have been done before the now
accepted classification on six lineages, just discriminating the two
original genetic groups. It is now well established that former Tc II
group is greatly heterogeneous comprising at least five diverse
subgroups [15,26,45].
In contrast to previous studies, the data presented here builds on
firm phylogenetic framework to explore functional diversity and
the strains used have been genotyped and extensively character-
ized [58], including the normally poorly represented sylvatic
DTUs TcIII and TcIV.
Similar clustering was obtained with either single linkage and
complete linkage was used to group the strains (data not shown). It
is clear from our result that indeed is possible to correlate a
biological property, in this case the sensitivity to a drug (most
probably associated to a genetic trait like lipid composition of the
plasma membrane), quantified by the cumulative effect over a dose
range, and not by a single parameter like the IC50, with the genetic
lineage. That way the whole information on the dose effect curve is
taken in account and not only a single dose, in which case,
threshold effects or cumulative effects are dismissed.
The results derived from this study, no matter the potential
medical significance, cannot be extrapolated to other drugs as the
responses to those would depend mainly on the action mechanism,
compensatory metabolic changes and detoxification systems
specific for each drug. In Trypanosoma cruzi has been demonstrated
that there is no in vivo cross-resistance to nitroheterocyclic drugs
(like BZN and nifurtimox) and imidazole derivatives (65) and
under that premise, the currently used drug for Chagas’ disease,
Benznidazol, was excluded from the joint analysis. The same
reason would be valid in case any future analysis with BZN reveals
a different cluster organization of the strains. Even when we were
tempted to do a cluster analysis with our data set from BZN
susceptibility data, they were limited enough to guarantee a
significant result and will be done as soon as we get supply of BZN.
Our results are in partial agreement with a recent report [40]
that has used a proteomic approach to identify DTU-specific
proteins and dissimilarities to correlate phylogenetic character
mapping in T. cruzi, as we also found a closer relationship between
DTUs VI and III, than to the other DTUs between them. This is
congruent with the phylogeny of T. cruzi established by other
markers, however, the cluster obtained in this report does not
reveal the same topology as those [39,40,42,44,45], in particular
the closer distances between DTU I and II. But in any case there is
a strong coincidence, supporting the notion that evolution of
Figure 5. Ultrastructural studies of antibiotics effects. A. CM17 untreated control; B. Silvio/X10 untreated control; C. CM17 PIM 0.4 mM for 4
hours; D and E. Silvio/X10 PIM 0.4 mM for 4 hours; F. CM17 PIM 4 mM for 4 hours; G. Silvio/X10 CE108B 4 mM for 4 hours; H. CM17 PIM 0.4 mM for 24 h;
I. Silvio/X10 PIM 0.4 mM for 24 hours; Bars in white represent 10 mm in F and I, and 5 mm in all others figures.
doi:10.1371/journal.pone.0040901.g005
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metabolic and biochemical properties are far from being
independent of evolution of genetic characters. Results from our
group based on a hierarchical analysis of the glycans family
(terminal fucose and enzymes responsible for that) exposed on the
surface of T. cruzi strains (Bonay et al, manuscript in preparation)
supports that view.
Even when the main objective of this study was not to establish
a phylogenetic mapping based on a biochemical/cell biology
property as is the drug sensitivity. The results obtained in this
report and the ones from Telleria et al. [40] provide the basis and
a conceptual framework to continue the analysis of population
structure of this complex organism and furthermore, to study
biochemical traits associated to fundamental genetic traits like the
membrane sterol composition of the different DTUs.
Our results strongly stimulate further studies on the efficacy
testing of these novel antibiotics in a murine model of T. cruzi
infection with different strains to correlate functional properties in
vivo and also encourage carrying out similar studies on clinically
relevant forms of the parasite by testing drugs currently in use or
undergoing clinical trials.
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